AS Merko Ehitus (TAL:MRK1T)

Ligand Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	543.1	539.05	466.3	409.63	339.38	315.92
Revenue Growth (YoY)	15.13%	15.60%	13.84%	20.70%	7.42%	-3.32%
Cost of Revenue	441.18	443.16	401.27	355.98	292.56	272.17
Gross Profit	101.92	95.89	65.04	53.66	46.81	43.75
Selling, General & Admin	27.28	26.94	23.74	19.94	17.54	17.62
Other Operating Expenses	1.24	1.39	0.08	1.26	-0.7	2.41
Operating Expenses	28.52	28.32	23.82	21.2	16.84	20.03
Operating Income	73.4	67.56	41.22	32.46	29.98	23.72
Interest Expense	-1.38	-1.82	-2.7	-1.18	-0.68	-0.72
Interest & Investment Income	3.93	3.93	2.44	2.26	2.13	1.5
Earnings From Equity Investments	4.8	4.86	10.22	3.52	0.8	-0.14
Currency Exchange Gain (Loss)	-0.65	-0.95	-0.17	-0.14	-0.01	-0.01
Other Non Operating Income (Expenses)	-0.3	-0.18	-0.17	-0.13	-0.2	-0.14
EBT Excluding Unusual Items	79.81	73.41	50.85	36.79	32.02	24.21
Gain (Loss) on Sale of Assets	2.92	2.92	0.96	0.31	0.11	0.25
Other Unusual Items	0.09	0.09	0.18	-	-	-
Pretax Income	82.81	76.41	51.98	37.1	32.13	24.46
Income Tax Expense	12.14	11.82	6.08	3	3.1	1.95
Earnings From Continuing Operations	70.67	64.59	45.9	34.1	29.02	22.5
Minority Interest in Earnings	0.03	0.07	0.15	0.54	0.12	0.49
Net Income	70.7	64.67	46.05	34.64	29.14	22.99
Net Income to Common	70.7	64.67	46.05	34.64	29.14	22.99
Net Income Growth	58.54%	40.44%	32.93%	18.87%	26.73%	41.33%
Shares Outstanding (Basic)	18	18	18	18	18	18
Shares Outstanding (Diluted)	18	18	18	18	18	18
EPS (Basic)	3.99	3.65	2.60	1.96	1.65	1.30
EPS (Diluted)	3.99	3.65	2.60	1.96	1.65	1.30
EPS Growth	58.54%	40.44%	32.93%	18.87%	26.73%	41.33%
Free Cash Flow	41.19	56.03	113.74	-42.9	-2.6	58.19
Free Cash Flow Per Share	2.33	3.17	6.43	-2.42	-0.15	3.29
Dividend Per Share	1.900	1.900	1.300	1.000	1.000	1.000
Dividend Growth	46.15%	46.15%	30.00%	-	-	-
Gross Margin	18.77%	17.79%	13.95%	13.10%	13.79%	13.85%
Operating Margin	13.51%	12.53%	8.84%	7.92%	8.83%	7.51%
Profit Margin	13.02%	12.00%	9.88%	8.46%	8.59%	7.28%
Free Cash Flow Margin	7.58%	10.39%	24.39%	-10.47%	-0.77%	18.42%
EBITDA	75.13	69.38	43.45	34.19	31.37	25.14
EBITDA Margin	13.83%	12.87%	9.32%	8.34%	9.24%	7.96%
D&A For EBITDA	1.73	1.82	2.24	1.73	1.39	1.42
EBIT	73.4	67.56	41.22	32.46	29.98	23.72
EBIT Margin	13.51%	12.53%	8.84%	7.92%	8.83%	7.51%
Effective Tax Rate	14.66%	15.47%	11.70%	8.07%	9.66%	7.99%

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.